New Science Ventures

NSV sources by going where the science is, deliberately targeting companies outside traditional tech and biotech hubs. It leverages the deep scientific networks of its investment team, which includes professionals with advanced degrees and direct industry experience. The firm emphasizes fundamental, science-based innovation with strong IP protection, often taking contrarian views that conventional VCs overlook.

NSV is explicitly flexible: it is willing to lead, follow, or serve as the sole investor in a round. This posture allows the firm to assemble the right syndicate for each company's stage and context. It does not require a minimum co-investor structure and can act unilaterally when it identifies a high-conviction, science-driven opportunity.

The firm invests across early-stage (including seed and start-up) and late-stage expansion. This broad mandate reflects its focus on supporting companies through value inflection points. The stage is tailored to the scientific maturity and capital needs of each opportunity.

NSV concentrates on life sciences and information technology. Specific sub-sectors evident in the portfolio include novel therapeutics, advanced materials (graphene electronics), satellite-based weather data, automated transit, 5G private networks, and radiation-hardened space chips. The common thread is science-based innovation addressing significant unmet needs.

Decision-making authority rests with the investment team, which includes Partner Andrew Abrams working from the London office. The firm operates with a lean structure; final investment decisions are made by the partnership, drawing on collective board-level and scientific expertise.

NSV operates a transatlantic model with offices in Greenwich, Connecticut and London. Its portfolio spans the United States and Europe, with confirmed companies in the UK, continental Europe, and the US. The firm explicitly invests outside traditional tech and life-science hubs.

There is no publicly disclosed philanthropic foundation, donor-advised fund, or impact-investing vehicle directly associated with New Science Ventures. The firm appears structured solely as a for-profit investment manager.